poseida_thera

/Poseida Therapeutics

About Poseida Therapeutics

This author has not yet filled in any details.
So far has created 18 blog entries.

Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual Retreat

SAN DIEGO, October 5th, 2017 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based clinical-stage company translating best-in-class gene therapy technologies into lifesaving cell therapies, today presented preclinical data on P-PSMA-101, the company’s PSMA-specific chimeric antigen receptor T cell (CAR-T) stem cell memory drug candidate for the treatment of prostate cancer, showing potent anti-tumor activity, a […]

By |October 5th, 2017|News|Comments Off on Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual Retreat

Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA-Specific CAR-T Stem Cell Memory Therapy for Patients with Multiple Myeloma

SAN DIEGO, Sept. 26, 2017 — Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene therapy technologies into lifesaving cell therapies, is now enrolling patients in its Phase 1 study of P-BCMA-101, the company’s lead investigational chimeric antigen receptor T cell (CAR-T) immunotherapy for the treatment of multiple myeloma.

“P-BCMA-101 combines a number of […]

By |September 26th, 2017|News|Comments Off on Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA-Specific CAR-T Stem Cell Memory Therapy for Patients with Multiple Myeloma

Poseida Therapeutics Presents Novel BCMA-Specific CAR-T Therapy at CAR-TCR Summit

SAN DIEGO, September 6th, 2017 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving cell therapies, today presented preclinical data on P-BCMA-101, the company’s BCMA-specific CAR-T drug candidate for the treatment of multiple myeloma, at the CAR-TCR Summit on T Cell Immunotherapies in Boston. SAN DIEGO, September 6th, 2017 […]

By |September 6th, 2017|News|Comments Off on Poseida Therapeutics Presents Novel BCMA-Specific CAR-T Therapy at CAR-TCR Summit

Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual Meeting

SAN DIEGO, June 5, 2017 – Poseida Therapeutics, Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced preclinical data demonstrating the use of the company’s proprietary high-fidelity genome editing system, NextGEN™ CRISPR, for production of allogeneic “universal donor” chimeric antigen receptor  T-cells (CAR-T). In a study presented today […]

By |June 5th, 2017|News|Comments Off on Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual Meeting

Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy

MENLO PARK, Calif. and SAN DIEGO, May 22, 2017 (GLOBE NEWSWIRE) — Teneobio, Inc. and Poseida Therapeutics, Inc. today announced that they have entered a commercial license agreement for the use of Teneobio’s UniDabs™, single-domain, human heavy chain only antibodies in Chimeric Antigen Receptor (CAR) T-cell therapy. Under the terms of the agreement Poseida […]

By |May 22nd, 2017|News|Comments Off on Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy

Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual Meeting

SAN DIEGO, April 4, 2017 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced preclinical data from the company’s B-cell maturation antigen (BCMA)-specific chimeric antigen receptor CAR T-cell (CAR-T) drug candidate, referred to as P-BCMA-101. Data demonstrated potent and persistent anti-tumor activity, elimination of tumors […]

By |April 4th, 2017|News|Comments Off on Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual Meeting

BioCentury Innovations: “Piggyback CAR Ride”

Emerging Company Profile published January 19, 2017

By |January 31st, 2017|Press|Comments Off on BioCentury Innovations: “Piggyback CAR Ride”

San Diego Union Tribune: “San Diego: Innovation Incubator”

Sunday Edition Union Tribune published September 18, 2016
Used with permission from the San Diego Union Tribune . Copyright 2015 The San Diego Union-Tribune, LLC. All rights reserved

By |January 31st, 2017|Press|Comments Off on San Diego Union Tribune: “San Diego: Innovation Incubator”

Poseida Therapeutics Appoints Debra Gessner as Vice President, Regulatory Affairs

SAN DIEGO, Jan. 3, 2017 — Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced that Debra Gessner has joined the company as vice president, regulatory affairs.

Ms. Gessner brings deep expertise in drug development, regulatory communications and strategy — including significant experience in gene therapy and immuno-oncology […]

By |January 3rd, 2017|News|Comments Off on Poseida Therapeutics Appoints Debra Gessner as Vice President, Regulatory Affairs

Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual Meeting

SAN DIEGO, December 5, 2016 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced preclinical data from the company’s B-cell maturation antigen (BCMA) specific chimeric antigen receptor (CAR) T-cell drug candidate, referred to as P-BCMA-101. Data demonstrated a superior stem cell memory phenotype and self-renewal […]

By |December 5th, 2016|News|Comments Off on Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual Meeting